Value of new performance information in healthcare: evidence from Japan.


Journal

International journal of health economics and management
ISSN: 2199-9031
Titre abrégé: Int J Health Econ Manag
Pays: United States
ID NLM: 101674352

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 27 11 2019
accepted: 07 08 2020
pubmed: 19 8 2020
medline: 17 8 2021
entrez: 19 8 2020
Statut: ppublish

Résumé

Mandatory measurement and disclosure of outcome measures are commonly used policy tools in healthcare. The effectiveness of such disclosures relies on the extent to which the new information produced by the mandatory system is internalized by the healthcare organization and influences its operations and decision-making processes. We use panel data from the Japanese National Hospital Organization to analyze performance improvements following regulation mandating standardized measurement and peer disclosure of patient satisfaction performance. Drawing on value of information theory, we document the absolute value and the benchmarking value of new information for future performance. Controlling for ceiling effects in the opportunities for improvement, we find that the new patient satisfaction measurement system introduced positive, significant, and persistent mean shifts in performance (absolute value of information) with larger improvements for poorly performing hospitals (benchmarking value of information). Our setting allows us to explore these effects in the absence of confounding factors such as incentive compensation or demand pressures. The largest positive effects occur in the initial period, and improvements diminish over time, especially for hospitals with poorer baseline performance. Our study provides empirical evidence that disclosure of patient satisfaction performance information has value to hospital decision makers.

Identifiants

pubmed: 32808057
doi: 10.1007/s10754-020-09283-1
pii: 10.1007/s10754-020-09283-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-357

Auteurs

Susanna Gallani (S)

Harvard Business School, 369 Morgan Hall, 15 Harvard Way, Boston, MA, 02163, USA. sgallani@hbs.edu.

Takehisa Kajiwara (T)

Graduate School of Business Administration, Kobe University, 2-1 Rokkodai, Nada-ku, Kobe, 657-8501, Japan.

Ranjani Krishnan (R)

The Eli Broad College of Business, Michigan State University, N207 North Business College Complex, 632 Bogue St, East Lansing, MI, 48824, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH